RecruitingNot ApplicableNCT06943469

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

Synbiotics in Partially Hydrolysed Formula for Improved skiN Barrier Function in Infants at Risk for Allergy (SPHINX Study)


Sponsor

Société des Produits Nestlé (SPN)

Enrollment

400 participants

Start Date

Apr 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.


Eligibility

Min Age: 1 DayMax Age: 14 Days

Inclusion Criteria10

  • Written informed consent has been obtained from at least one parent or legally acceptable representative (LAR), if applicable
  • Infant gestational age ≥ 37 completed weeks
  • Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg
  • Infant postnatal age ≤ 14 days (date of birth = day 0) at enrollment
  • Infant from singleton birth or infant from multiple births may if all birth siblings are enrolled.
  • At least one biological parent or sibling has (or had) a medically diagnosed history of allergy, based on response to a simple screening questionnaire
  • a. For the breastfed reference group only: infant is exclusively breastfed since birth with no intake of formula, and their parent(s) have the intention to continue exclusive breastfeeding until at least 4 months of age.
  • or b. For the randomized formula-fed groups only: infant is exclusively or predominantly formula-fed in the 24 hours prior to enrollment, with formula feeding representing at least 75% of total daily feeds. The decision to introduce formula feeding was independently made by the parents before enrollment.
  • Parents/LAR must be able to provide evidence of parental authority and identity.
  • Infant's parent(s)/LAR must understand the informed consent form and other study documents and are willing and able to fulfill the requirements of the study protocol.

Exclusion Criteria5

  • Infectious, metabolic, congenital, genetic, gastrointestinal illness or any other condition (e.g., gastrointestinal surgery) that could impact oral feeding, growth or study outcomes.
  • Infants with special dietary needs other than standard infant formula (e.g., extensively hydrolyzed formula, amino acid formula, special formula for metabolic diseases) or requiring tube feeding.
  • Infant has already been diagnosed with allergy by a physician, including AD and/or cow's milk allergy.
  • Infant is currently participating or has previously participated in another clinical trial prior to enrollment.
  • Infant's parents or LARs have not reached legal age of majority (18 years).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTest formula

Partially hydrolyzed formula with synbiotics

OTHERControl formula

Intact protein formula without synbiotics


Locations(23)

AZ Sint-Jan Brugge-Oostende AV - Campus Sint-Jan

Bruges, Belgium

Universitair Ziekenhuis Brussel - Kinderziekenhuis

Brussels, Belgium

Clinique Ste Elisabeth

Namur, Belgium

CHU Amiens Picardie

Amiens, France

CHU de Caen

Caen, France

CHU de Grenoble Alpes

Grenoble, France

Hôpital de la Croix Rousse

Lyon, France

Hôpital Charles Nicolle

Rouen, France

CHRU de Tours

Tours, France

Charite-Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)

Berlin, Germany

Evangelisches Krankenhaus Düsseldorf - Frauenklinik

Düsseldorf, Germany

Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Frankfurt

Frankfurt, Germany

Evangelisches Waldkrankenhaus Spandau

Spandau, Germany

Marien Hospital Wesel GmbH

Wesel, Germany

Hospital Teresa Herrera

A Coruña, Spain

HU Torrecárdenas

Almería, Spain

Hospital Quiron Salud Barcelona

Barcelona, Spain

Hospital Universitario Severo Ochoa

Madrid, Spain

Grupo Pediátrico Uncibay

Málaga, Spain

Instituto Hispalense de Pediatria (IHP)

Seville, Spain

Hospital Universitari de Tarragona Joan XXIII

Tarragona, Spain

Hospital Universitari Sant Joan de Reus

Tarragona, Spain

HCU Lozano Blesa

Zaragoza, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06943469


Related Trials